Transparency Market Research in its new report titled, “Ophthalmic Anesthetic Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 – 2026,” provides key insights on the ophthalmic anesthetic drugs market. The TMR report anticipates that the increased incidence and prevalence of disorders related to eyes such as diabetic retinopathy among the aging population, macular degeneration, and presbyopia will drive the ophthalmic anesthetic drugs market during the forecast period i.e, 2018-2026. Rise in number of ophthalmic operations to correct eye-related disorders is also one of the factor fuelling the expansion of the global ophthalmic anesthesia market. However, risks associated with ophthalmic anesthetics and less awareness about eye-related disorders, especially in developing countries, are some major restraining factors for the global ophthalmic anesthesia market, says the report.
The TMR report states that ophthalmic anesthetic molecules that are applied topically block conduction of nerve impulses when applied to conjunctiva and cornea. The ocular surface is innervated by the multiple branches of trigeminal nerve. Topical anesthetics decrease the penetrability of sodium ions to reduce the circulation of nerve impulse, increase the excitation threshold, and prevent the production and transmission of nerve impulses. These activities of anesthetics inhibit transmission alongside the axons, keeping the brain from detecting nosogenic stimuli, according to the report. Ophthalmic anesthetics are used in medical conditions for the calculation of intraocular pressure by applanation tonometry, ophthalmic surgery, elimination of superficial foreign groups, and for the early assessment of eye trauma. Hence, ophthalmic anesthetics are used in several medical conditions. Patients generally receive a single administration of ophthalmic anesthetics, and their repeated use is avoided if possible. Anesthetic drugs are also used for relief from initial disease or injury, followed by additional use, says the report.
The TMR report has segmented the global ophthalmic anesthesia market based on type and region. In terms of type, the global market is divided into topical (surface) anesthesia, regional (local) anesthesia, and general anesthesia. The topical (surface) anesthesia segment can be further categorized into facial block, retrobulbar block, and peribulbar block. On the basis of geographical perspective, the global ophthalmic anesthesia market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global ophthalmic anesthesia market due to availability of advanced surgical operations and anesthetic surgeons. Awareness among the people about ocular diseases/disorders is also a major factor boosting the market in the region. The ophthalmic anesthesia market in Asia Pacific is anticipated to expand at a rapid pace due to increased awareness about eye disorders and increased health care expenses. Lack of awareness about diseases and unavailability of advanced technology and skilled anesthetic surgeons in underdeveloped countries such as Lebanon, Syria, Cyprus, Turkey, and Iraq are likely to restrain the ophthalmic anesthesia market in Middle East & Africa.
Some of the major players in the global ophthalmic anesthesia market are profiled in this report to give a better competitive analysis of the market and these include Akorn, Inc., Alves Health care, Alcon Research, Ltd., Bausch & Lomb Incorporated, Hospira Inc., ALLERGAN, and Cipla Inc.
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453